The effectiveness of treatment of benign oesophageal strictures resistant to the balloon dilation by biodegradable stents

ČERNÁ, M, M KÖCHER, Vlastimil VÁLEK, Jiří PÁNEK and Tomáš ANDRAŠINA. The effectiveness of treatment of benign oesophageal strictures resistant to the balloon dilation by biodegradable stents. In CIRSE 2012. 2012. ISSN 0174-1551. Available from: https://dx.doi.org/10.1007/s00270-012-437-6.

Basic information

• Original name: The effectiveness of treatment of benign oesophageal strictures resistant to the balloon dilation by biodegradable stents
• Authors: ČERNÁ, M, M KÖCHER, Vlastimil VÁLEK, Jiří PÁNEK and Tomáš ANDRAŠINA.
• Edition: CIRSE 2012, 2012.

Other information

• Type of outcome: Conference abstract
• Confidentiality degree: is not subject to a state or trade secret
• Impact factor: Impact factor: 2.138
• ISSN: 0174-1551
• Doi: http://dx.doi.org/10.1007/s00270-012-437-6

Abstract

Purpose The aim of our study is to present three-year experience in the treatment of benign oesophageal strictures resistant to the balloon dilation by biodegradable stents. Material and Methods From 2007 to 2011 we treated 22 patients (16 men, 6 women, mean age 68.2 years) by 29 biodegradable SX ELLA esophageal stent for benign oesophageal strictures resistant to the balloon dilation. Biodegradable SX ELLA esophageal stent is a self-expandable stent braided from absorbable polydioxanone monofilament. The etiology of stricture was caustic in 2 patients, actinotherapy in 3, postoperative in 7, chronic mycosis in 1 and gastroesophageal reflux disease in 9 patients. Statistical analysis was performed by Kaplan-Meier analysis. Results Stent placement was successful in 21 patients. Technical success was 96.5%. Pain was observed in 2 patients, migration in 2, fistula in one and massive arterial bleeding in one. The mean follow-up was 13.9 months (1-57 months). Primary patency rate was 83.1% (SE: 3.9%), 67.5% (SE: 5%), 58% (SE: 5.9%) a 48.4% (SE: 7.1%) at 6, 12, 24 and 36 months, respectively. Primary patency was 8.7 months, 95% CI: 3.5–13.9 months. Primary-assisted patency (additional effective balloon dilatation) was 12.4 months, 95% CI: 6.4–18.4 months. Conclusion The use of biodegradable SX ELLA esophageal stent is feasible and safe. Its use eliminates the need of removing the stent after long-term dwelling in situ as well as the risk of complications related to the removal. However, mucosal hyperplasia and restenosis are relatively frequent complications.